FDA Device Decisions, September 2025: Spectacle Lenses to Slow Myopia in Children, Three De Novo Grants and Four Original PMAs
One of FDA's three De Novo grants in September 2025 went to Essilor Stellest (DEN250016), spectacle lenses that correct myopia and slow its progression in children aged 6 to 12 at the start of treatment. The grant created a new classification for prescription spectacle lenses to reduce the progression of myopia.
Its special controls combine premarket clinical validation with postmarket surveillance, and the order requires a postmarket clinical study of whether myopia progression rebounds after the lenses are discontinued.
Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 257 510(k)s in September 2025, granted 3 De Novo requests and approved 4 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.
Counts by pathway
September 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.
| Pathway | September 2025 | August 2025 | September 2024 |
|---|---|---|---|
| 510(k) | 257 | 251 | 227 |
| De Novo | 3 | 1 | 3 |
| PMA (original) | 4 | 6 | 1 |
| PMA supplement | 197 | 179 | 174 |
Records held in RA Craft Database, decisions through August 31, 2026.
510(k) clearances were 6 more than in August and above September 2024 (227). There were 3 De Novo grants.
The busiest product codes
September's 510(k)s spread across 179 product codes. QIH (automated radiological image processing software) led with 11, followed by GEX (powered laser surgical instrument) with 6 and GEI (electrosurgical, cutting & coagulation & accessories) and LLZ (system, image processing, radiological) with 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.
De Novo: three classifications
September's three De Novo grants, all Class II, with the classification names and regulation numbers from each Classification Order:
- KMT2A Breakapart FISH Probe Kit PDx (DEN240067, Cytocell Limited): Revumenib eligibility detection system (21 CFR 864.1885)
- Biolinq Shine Autonomous Time-in-Range Microsensor (DEN240080, Biolinq Incorporated): Glucose range monitoring system (21 CFR 862.1359)
- Essilor® Stellest® (DEN250016, Essilor of America, Inc.): Prescription spectacle lenses to reduce the progression of myopia (21 CFR 886.5845)
"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.
Stellest is indicated for children with non-diseased eyes and spherical equivalent refraction of −0.75 D to −4.50 D with astigmatism up to 1.50 D.
Original PMAs: four approvals
- saypha® MagIQ™ (P240008, Croma-Pharma GmbH): a hyaluronic acid filler with lidocaine for moderate to severe facial wrinkles and folds such as nasolabial folds (product code LMH)
- Womed Leaf® Resorbable Adhesion Barrier (P240015, Womed SAS): a resorbable film placed in the uterus after hysteroscopic surgery for intrauterine adhesions, to reduce their recurrence (MCN)
- FINEVISION HP Trifocal IOL (P240038, Beaver-Visitec International, Inc.): a trifocal intraocular lens for distance, intermediate and near vision after cataract removal (HQL)
- Medtronic Altaviva™ System (P240011, Medtronic Neuromodulation): a leadless tibial nerve stimulator implanted above the ankle for urge urinary incontinence (QPT)
September also brought 197 PMA supplements, which cover changes to already approved PMA devices among other things.
Three devices worth a closer read
1. Essilor® Stellest® (DEN250016, De Novo). One of its three special controls covers premarket clinical validation and postmarket surveillance: change in refractive error, cumulative effect, adverse events, rebound after discontinuation and visual performance. The order requires a postmarket clinical study that recruits earlier participants and measures axial length and refraction 6 and 12 months after they stop wearing the lenses, with enrollment milestones.
2. Biolinq Shine Autonomous Time-in-Range Microsensor (DEN240080, De Novo). An intradermal glucose sensor with a color-changing light that signals changes in glucose, for adults 22 and older not on insulin; an app adds more detail and relates glucose to meals, rest and activity. Among its six special controls, the labeling must state that the device is not for insulin dosing, medication adjustment or other acute medical decisions.
3. KMT2A Breakapart FISH Probe Kit PDx (DEN240067, De Novo). A FISH test that detects KMT2A rearrangements in bone marrow from patients with acute leukemia, used as a companion diagnostic for revumenib. Most companion diagnostics are approved through PMA; this one was classified into Class II through De Novo. Its special controls include training for testing sites on result interpretation, with demonstrated proficiency.
Compare the three devices
Open DEN250016, DEN240080 and DEN240067, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.
Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles